{"url_path":"/sec/tpst/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-224289-index.html","accession_number":"0001193125-26-224289","cik":"0001544227","ticker":"TPST","issuer_name":"Tempest Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1544227/0001193125-26-224289-index.html","primary_entity_key":"0001544227","primary_entity_name":"Tempest Therapeutics, Inc."},"word_count":544,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nThe following exhibits are incorporated by reference or filed as part of this report.\n\n \n\n \n\n \n\nIncorporation by Reference\n\nExhibit Number\n\nDescription of Exhibit\n\nForm\n\nFile Number\n\nExhibit\n\nFiling Date\n\nFiled or Furnished Herewith\n\n3.1\n\n[Restated Certificate of Incorporation of the Registrant, as amended](https://www.sec.gov/Archives/edgar/data/1544227/000155837019005038/mlnd-20190331ex31b53fa83.htm)\n\n10-Q\n\n001-35890\n\n3.1\n\n5/15/2019\n\n \n\n3.2\n\n[Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 24, 2021](https://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex31.htm)\n\n8-K\n\n001-35890\n\n3.1\n\n6/28/2021\n\n \n\n3.3\n\n[Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on June 25, 2021](https://www.sec.gov/Archives/edgar/data/1544227/000119312521201157/d196630dex32.htm)\n\n8-K\n\n001-35890\n\n3.2\n\n6/28/2021\n\n \n\n3.4\n\n[Certificate of Designation of Series A Junior Participating Preferred Stock filed with the Secretary of State of the State of Delaware on October 10, 2023](https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808dex31.htm)\n\n8-K\n\n001-35890\n\n3.1\n\n10/11/2023\n\n \n\n3.6\n\n[Certificate of Amendment to the Restated Certificate of Incorporation of the Company, as filed with the Secretary of State of the State of Delaware on April 4, 2025](https://www.sec.gov/Archives/edgar/data/1544227/000119312525073987/d905141dex31.htm)\n\n8-K\n\n001-35890\n\n3.1\n\n4/7/2025\n\n \n\n3.6\n\n[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1544227/000119312521281694/d222030dex31.htm)\n\n8-K\n\n001-35890\n\n3.1\n\n9/24/2021\n\n \n\n4.1\n\n[Form of Pre-Funded Warrant](https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/d85035dex41.htm)\n\n8-K\n\n001-35890\n\n4.1\n\n3/23/2026\n\n \n\n4.2\n\n[Form of Common Warrant](https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/d85035dex42.htm)\n\n8-K\n\n001-35890\n\n4.2\n\n3/23/2026\n\n \n\n10.1\n\n[Form of Securities Purchase Agreement](https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/d85035dex101.htm)\n\n8-K\n\n001-35890\n\n10.1\n\n3/23/2026\n\n \n\n10.2\n\n[Form of Registration Rights Agreement](https://www.sec.gov/Archives/edgar/data/1544227/000119312526118618/d85035dex102.htm)\n\n8-K\n\n001-35890\n\n10.2\n\n3/23/2026\n\n \n\n10.3\n\n[Funding Commitment Letter](tpst-ex10_3.htm)\n\n \n\n \n\n \n\n \n\nX\n\n10.4\n\n[Waiver Letter Agreement](tpst-ex10_4.htm)\n\n \n\n \n\n \n\n \n\nX\n\n31.1\n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](tpst-ex31_1.htm)\n\n \n\n \n\n \n\n \n\nX\n\n31.2\n\n[Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of 2002](tpst-ex31_2.htm)\n\n \n\n \n\n \n\n \n\nX\n\n32.1^\n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) and 15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002](tpst-ex32_1.htm)\n\n \n\n \n\n \n\n \n\nX\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\nX\n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n \n\n \n\n \n\n \n\nX\n\n104\n\nCover Page formatted as inline XBRL with applicable taxonomy extension contained in Exhibit 101.\n\n \n\n \n\n \n\n \n\nX\n\n^ These certifications are being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n36\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nTEMPEST THERAPEUTICS, INC.\n\n \n\n \n\n \n\nBy:\n\n \n\n/s/ Matthew Angel\n\nMatthew Angel\n\nChief Executive Officer & President (Principal Executive Officer)\n\n \n\n \n\nBy:\n\n \n\n/s/ Nicholas Maestas\n\nNicholas Maestas\n\nChief Financial Officer & Head of Corporate Strategy (Principal Financial Officer)\n\n \n\n \n\n \n\nDate: May 14, 2026\n\n37"}